Ascentage Pharma GIST Drug Data Published in Nature
Ticker: AAPG · Form: 6-K · Filed: Nov 25, 2025 · CIK: 2023311
Sentiment: neutral
Topics: publication, clinical-trial-data, oncology
TL;DR
Ascentage Pharma's GIST drug olverembatinib data published in Nature - looks promising.
AI Summary
Ascentage Pharma Group International announced on November 24, 2025, that its Phase Ib study results for olverembatinib in gastrointestinal stromal tumors (GIST) were published in Nature's Signal Transduction and Targeted Therapy. The publication details safety, efficacy, and the novel mechanism of action for the drug.
Why It Matters
Publication in a prestigious journal like Nature's Signal Transduction and Targeted Therapy lends significant credibility to the drug's potential and mechanism, potentially influencing investor and physician perception.
Risk Assessment
Risk Level: low — This filing is an informational press release publication, not a material financial event or change in business operations.
Key Players & Entities
- Ascentage Pharma Group International (company) — Registrant
- Olverembatinib (drug) — Drug studied
- Nature's Signal Transduction and Targeted Therapy (publication) — Journal of publication
- November 24, 2025 (date) — Date of press release
FAQ
What specific data on olverembatinib was published in Nature's Signal Transduction and Targeted Therapy?
The publication details Phase Ib safety, efficacy, and novel mechanism data for olverembatinib in gastrointestinal stromal tumors.
What is the significance of the publication in Nature's Signal Transduction and Targeted Therapy?
Publication in this journal signifies a high level of scientific validation and peer review for the study's findings.
What type of cancer is olverembatinib being studied for in this publication?
Olverembatinib is being studied for gastrointestinal stromal tumors (GIST).
When was the press release announcing this publication issued?
The press release was issued on November 24, 2025.
Is Ascentage Pharma Group International a US-based company?
No, Ascentage Pharma Group International is a foreign private issuer with its principal executive offices located in Suzhou, Jiangsu, China.
Filing Stats: 212 words · 1 min read · ~1 pages · Grade level 15.4 · Accepted 2025-11-25 08:00:22
Filing Documents
- ea0265104-6k_ascentage.htm (6-K) — 11KB
- ea026510401ex99-1_ascentage.htm (EX-99.1) — 23KB
- ex99-1_001.jpg (GRAPHIC) — 11KB
- 0001213900-25-114395.txt ( ) — 51KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number: 001-42484 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE On November 24, 2025, Ascentage Pharma Group International issued a press release entitled “Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy”. A copy of the press release is furnished as Exhibit 99.1 to this Report. 1 INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Press Release dated November 24, 2025 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: November 25, 2025 /s/ Dajun Yang Name: Dajun Yang Title: Chief Executive Officer 3